Trial Profile
A clinical trial of DS-8201a in HER2 positive(HER2≥1) metastatic/recurrent uterine carcinosarcoma patients (NCCH1615,STATICE trial)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2023
Price :
$35
*
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Carcinoma; Sarcoma; Uterine cancer
- Focus Therapeutic Use
- Acronyms STATICE
- 28 Mar 2023 Results published in the Journal of Clinical Oncology
- 15 Apr 2022 Planned number of patients changed from 25 to 35.
- 15 Apr 2022 Status changed from active, no longer recruiting to completed.